TTR and hemophilia A: The use of a larger number of copies of CRM8 can significantly enhance the mTTR promoter, but presence of an mTTR enhancer is still necessary to provide maximum TTR promoter activity, that is an obstacle to its use in gene therapies with a large transgene coding sequence, as in the case of hemophilia A [196,307].